Matrivax Research & Development Corporation is researching and developing a novel technology termed Protein Capsular Matrix Vaccine (PCMV) as an alternative to polysaccharide-protein conjugate vaccines. In a PCMV, polysaccharide antigens are entrapped in a cross-linked protein ‘carrier’ matrix. This process is simpler than conjugate vaccines and should yield polysaccharide vaccines that elicit TH-cell ‘memory’, are highly efficacious, and less expensive to manufacture.
Typhoid fever, caused by Salmonella enterica serovar Typhi, is a disease that afflicts ~16 million people worldwide, resulting in 600,000 deaths, annually. Although typhoid fever vaccines are commercially available, there are significant limitations. Ty21a is an oral vaccine that requires a multi-dose regimen; whereas Typherix® and TyphimVi® are parenteral and associated with local reactogenicity. The existing typhoid vaccines confer variable, ~70%, protective efficacy, do not protect young children (\u3c2 years old), and are not used for routine immunization.
Please click Additional Files below to see the full abstract
